--- title: "Kura Oncology | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286151419.md" datetime: "2026-05-12T20:20:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286151419.md) - [en](https://longbridge.com/en/news/286151419.md) - [zh-HK](https://longbridge.com/zh-HK/news/286151419.md) --- # Kura Oncology | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M Revenue: As of FY2026 Q1, the actual value is USD 18.27 M, missing the estimate of USD 25.92 M. EPS: As of FY2026 Q1, the actual value is USD -0.83, missing the estimate of USD -0.8244. #### Revenue - **Product Revenue, Net**: Kura Oncology, Inc. reported $5.8 million for the three months ended March 31, 2026, compared to none for the same period in 2025. - **Collaboration Revenue**: Kura Oncology, Inc. recorded $12.5 million for the three months ended March 31, 2026, a decrease from $14.1 million for the same period in 2025. - **Total Revenue**: Total revenue for Kura Oncology, Inc. was $18.3 million for the three months ended March 31, 2026, up from $14.1 million for the same period in 2025. #### Operational Metrics - **Net Loss**: Kura Oncology, Inc. reported a net loss of - $73.3 million for the three months ended March 31, 2026, compared to a net loss of - $57.4 million for the same period in 2025. - **Research and Development Expenses**: These expenses for Kura Oncology, Inc. were $65.3 million for the three months ended March 31, 2026, an increase from $56.0 million for the same period in 2025, primarily driven by the advancement of ziftomenib combination trials, including KOMET-017. - **Selling, General and Administrative Expenses**: Kura Oncology, Inc.’s SG&A expenses were $31.6 million for the three months ended March 31, 2026, up from $22.8 million for the same period in 2025, reflecting commercialization-related investments. - **Cost of Product Sales**: Cost of product sales for Kura Oncology, Inc. was $0.3 million for the three months ended March 31, 2026, compared to none for the same period in 2025. - **Other Income, Net**: Kura Oncology, Inc. had other income, net, of $5.5 million for the three months ended March 31, 2026, compared to $7.5 million for the same period in 2025. - **Income Tax Expense**: Income tax expense for Kura Oncology, Inc. was $0.008 million for the three months ended March 31, 2026, compared to $0.226 million for the same period in 2025. - **Non-Cash, Share-Based Compensation Expense**: The net loss for Kura Oncology, Inc. includes $8.4 million in non-cash, share-based compensation expense for the three months ended March 31, 2026, compared to $7.8 million for the same period in 2025. #### Balance Sheet and Cash Position - **Cash, Cash Equivalents and Short-Term Investments**: As of March 31, 2026, Kura Oncology, Inc. had $580.8 million in cash, cash equivalents and short-term investments, down from $667.2 million as of December 31, 2025. - **Working Capital**: Kura Oncology, Inc.’s working capital was $522.3 million as of March 31, 2026, compared to $591.7 million as of December 31, 2025. - **Total Assets**: Total assets for Kura Oncology, Inc. were $652.6 million as of March 31, 2026, compared to $738.4 million as of December 31, 2025. - **Long-term Liabilities**: Kura Oncology, Inc. reported long-term liabilities of $443.2 million as of March 31, 2026, compared to $447.3 million as of December 31, 2025. - **Accumulated Deficit**: The accumulated deficit for Kura Oncology, Inc. was - $1,247.4 million as of March 31, 2026, compared to - $1,174.1 million as of December 31, 2025. - **Stockholders’ Equity**: Stockholders’ equity for Kura Oncology, Inc. was $107.9 million as of March 31, 2026, compared to $174.1 million as of December 31, 2025. #### Unique Operational Metrics - **KOMZIFTI Launch Performance**: KOMZIFTI generated $5.8 million in net product revenue in its first full quarter of commercialization (Q1 2026). - **New Patient Starts and Prescriptions**: The company reported 85 new patient starts and 157 total prescriptions for KOMZIFTI during the first full quarter. - **Payer Coverage**: Over 93% payer coverage has been achieved for KOMZIFTI, with favorable positioning across plans covering more than 12 million lives. - **Clinical Development Progress**: Kura Oncology, Inc. is advancing ziftomenib across the Acute Myeloid Leukemia (AML) treatment continuum, with ongoing site activation and patient enrollment for KOMET-017 (Phase 3 Frontline Program), KOMET-008 (FLT3 Relapsed/Refractory Population), and KOMET-007 (FLT3 Frontline Population). The first patient has been dosed in the Japanese Registrational Trial (Phase 2) for R/R NPM1-m AML. - **Solid Tumor Pipeline**: Proof-of-mechanism data for darlifarnib in combination with cabozantinib in clear cell renal cell carcinoma showed a 44% objective response rate (ORR), 94% disease control rate (DCR), and tumor shrinkage in 75% of patients. #### Outlook / Guidance Kura Oncology, Inc. anticipates its cash, cash equivalents, and short-term investments of $580.8 million as of March 31, 2026, combined with $180 million in anticipated collaboration payments, will fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 frontline trial, expected in 2028. The company expects multiple value-driving catalysts in 2026 across commercial and clinical development, including driving KOMZIFTI differentiation, sustained quarter-over-quarter revenue growth, and presenting various clinical data readouts for ziftomenib and darlifarnib programs. Additionally, Kura Oncology, Inc. plans to advance KO-7246, a next-generation menin inhibitor, into IND-enabling studies for diabetes and cardiometabolic disease. ### Related Stocks - [KURA.US](https://longbridge.com/en/quote/KURA.US.md) ## Related News & Research - [Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress | KURA Stock News](https://longbridge.com/en/news/286111526.md) - [Research Analysts Set Expectations for Kura Oncology FY2030 Earnings](https://longbridge.com/en/news/271652278.md) - [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md) - [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md) - [OPC Energy Q1 FY26 adjusted net profit climbs 18% to $33 million; EBITDA rises 10% to $124 million](https://longbridge.com/en/news/287057458.md)